Latest Innovation News

Prescient Therapeutics has launched a $7 million Share Purchase Plan at a notable discount to fund the next phase of clinical trials for its promising PTX-100 cancer therapy. The capital raise aims to accelerate progress toward regulatory approval and patient access.

Artrya Limited announces a strategic leadership reshuffle with co-founder John Konstantopoulos stepping into the CEO role as the company prepares for its U.S. commercial launch of the Salix® AI-powered platform.

Vinyl Group unveils its FY26 vision, shifting focus from growth to scalable profitability by leveraging AI-driven technology to connect millions of music creators, fans, and brands.

Biome Australia has reported record-breaking sales revenue for FY25, driven by strong domestic demand and promising international expansion. The company is on track to deliver its first full-year net profit and meet ambitious growth targets.

Copper Search Limited has secured two key exploration licences in South Australia's Eromanga Basin for Heavy Mineral Sands, setting the stage for a fully funded drilling campaign later this year. The company is also progressing copper-gold projects in New South Wales with government co-funding applications underway.

Norwood Systems has extended the repayment date on its key loan facility to July 31, 2025, with the principal reduced to $318,341 following significant repayments. This move supports the company’s ongoing growth initiatives, including its recent Optus contract win.

Sprintex Limited has extended convertible note and loan agreements totaling A$2.85 million, bolstering financial flexibility as it prepares for a significant sales trial with the Van Drie Group that could unlock over A$8.5 million in revenue.

Next Science Limited has agreed to sell most of its assets to Demetra Holdings for US$50 million, with plans to return an estimated US$30 million net proceeds to shareholders pending approval.

Raptis Group Limited has appointed Russell Garnett as its new CEO and Managing Director, effective July 1, 2025, with a remuneration package heavily weighted towards long-term performance incentives.

Rhythm Biosciences has obtained a $1 million non-dilutive loan backed by its FY2025 R&D Tax Incentive rebate, aiming to accelerate the commercial rollout of its ColoSTAT® test and expand its geneType™ platform.

Optiscan Imaging Ltd has commenced a landmark clinical study at Royal Melbourne Hospital, testing its cutting-edge InVue® and InForm™ devices to improve breast cancer surgery precision. The study aims to generate critical data for US FDA approval and could redefine surgical oncology workflows.

Electro Optic Systems has received A$60 million following the finalisation of a major contract, lifting its cash balance to approximately A$130 million as of June 30, 2025.